# ANAVEX2-73 Study in Patients With Rett Syndrome

> **NCT03941444** · PHASE3 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 33 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** ANAVEX2-73
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03941444
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941444, "ANAVEX2-73 Study in Patients With Rett Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03941444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*